Literature DB >> 3622556

Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma.

T Cerny, S E Owens, S A Mackenzie, P M Nuttall, A K Gosh, D B Smith, N Thatcher.   

Abstract

Immunoscintigraphy was performed in 25 patients with malignant melanoma using a 99mTc labelled monoclonal antibody (225.28S). In four cases, imaging was repeated following treatment with recombinant gamma interferon. In 11 cases, tissue samples of metastatic lesions were investigated for the expression of melanoma associated antigens by immunohistochemical techniques. Overall, 59% of known lesions were detected by imaging. The highest rates of detection were in bone, liver and lymph nodes and the lowest in lung, stomach and bowel. Six lesions were detected which had not shown up on routine clinical and radiological examination. There was no evidence of enhanced or induced HMW-MAA expression following interferon treatment. This technique has been found to be useful in staging patients and has been free from side effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3622556     DOI: 10.1007/bf00289024

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

2.  Immunoscintigraphy with 123I, 99mTc and 111In-labelled F(ab')2 fragments of monoclonal antibodies to a human high molecular weight-melanoma associated antigen.

Authors:  G L Buraggi; L Callegaro; A Turrin; N Cascinelli; A Attili; H Emanuelli; M Gasparini; G Deleide; G Plassio; M Dovis
Journal:  J Nucl Med Allied Sci       Date:  1984 Oct-Dec

3.  Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma.

Authors:  A G Siccardi; G L Buraggi; L Callegaro; G Mariani; P G Natali; A Abbati; M Bestagno; V Caputo; L Mansi; R Masi
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

4.  Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.

Authors:  P Giacomini; F Veglia; P Cordiali Fei; T Rehle; P G Natali; S Ferrone
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

5.  Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments.

Authors:  G L Buraggi; L Callegaro; G Mariani; A Turrin; N Cascinelli; A Attili; E Bombardieri; G Terno; G Plassio; M Dovis
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

Review 6.  Human melanoma-associated antigens identified with monoclonal antibodies.

Authors:  B S Wilson; P Giacomini; K Imai; P G Natali; T Nakanishi; G Ruberto; S Ferrone
Journal:  Ric Clin Lab       Date:  1982 Oct-Dec

7.  Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies.

Authors:  B S Wilson; K Imai; P G Natali; S Ferrone
Journal:  Int J Cancer       Date:  1981-09-15       Impact factor: 7.396

  7 in total
  6 in total

1.  European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group.

Authors:  A G Siccardi; G L Buraggi; P G Natali; G A Scassellati; G Viale; S Ferrone
Journal:  Eur J Nucl Med       Date:  1990

2.  Primary malignant melanoma of the oesophagus with a left atrial metastasis.

Authors:  M Chello; A R Marchese; A Panza; P Mastroroberto; F Di Lello
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

3.  Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering.

Authors:  J Xiang; J Koropatnick; Y Qi; X Luo; T Moyana; K Li; Y Chen
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

4.  A comparative study of the relative sensitivity and specificity of radiolabelled monoclonal antibody and computerised tomography in the detection of sites of disease in human malignant melanoma.

Authors:  A T Elliott; R M MacKie; T Murray; V R Doherty; F G Adams
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

Review 5.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

6.  Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma.

Authors:  M Koizumi; K Endo; Y Watanabe; T Saga; H Sakahara; J Konishi; Y Arano; Y Miyachi; M Kashihara-Sawami; S Imamura
Journal:  Jpn J Cancer Res       Date:  1988-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.